We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Chemours (CC) Up 34% in 3 Months: What's Driving the Stock?
Read MoreHide Full Article
Shares of The Chemours Company (CC - Free Report) have shot up around 34% over the last three months. The company has also significantly outperformed its industry’s gain of roughly 10.7% to over the same time frame.
Chemours has a market cap of roughly $10.1 billion and average volume of shares traded in the last three months is around 2,069.6K. The company has an expected long-term earnings per share growth of around 15.5%.
Let’s take a look into the factors that are driving this chemical maker’s stock.
Driving Factors
Strong second-quarter results and upbeat outlook have provided a boost to the company’s shares. Chemours recorded net income of $161 million or 84 cents per share in second-quarter 2017, against net loss of $18 million or 10 cents reported a year ago. Net sales for the quarter were $1,588 million, up roughly 15% year over year. Sales were driven by higher volumes across the board.
Chemours, in August, raised its full-year 2017 outlook on the back of solid second-quarter results. The company now expects adjusted EBITDA for 2017 to be $1.3-$1.4 billion compared with its earlier view of $1.15-$1.25 billion.
The revised guidance takes into account the gains from Chemours’ transformation plan initiatives, reduced transformation-related costs in the second half and strength across the company’s major end markets.
Chemours is expected to benefit from strength across its portfolio and improving end market conditions through the remainder of 2017. It is also well placed to gain from its sustained efforts to reduce costs, improve cash generation and strengthen the balance sheet. Moreover, the company is anticipated to continue to benefit from increased customer adoption of both Ti-Pure titanium dioxide and Opteon refrigerants.
Kraton has expected earnings growth of 7.2% for the current year.
FMC has expected long-term earnings growth of 11.3%.
Orion Engineered Carbons has expected earnings growth of 19% for the current year.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Chemours (CC) Up 34% in 3 Months: What's Driving the Stock?
Shares of The Chemours Company (CC - Free Report) have shot up around 34% over the last three months. The company has also significantly outperformed its industry’s gain of roughly 10.7% to over the same time frame.
Chemours has a market cap of roughly $10.1 billion and average volume of shares traded in the last three months is around 2,069.6K. The company has an expected long-term earnings per share growth of around 15.5%.
Let’s take a look into the factors that are driving this chemical maker’s stock.
Driving Factors
Strong second-quarter results and upbeat outlook have provided a boost to the company’s shares. Chemours recorded net income of $161 million or 84 cents per share in second-quarter 2017, against net loss of $18 million or 10 cents reported a year ago. Net sales for the quarter were $1,588 million, up roughly 15% year over year. Sales were driven by higher volumes across the board.
Chemours, in August, raised its full-year 2017 outlook on the back of solid second-quarter results. The company now expects adjusted EBITDA for 2017 to be $1.3-$1.4 billion compared with its earlier view of $1.15-$1.25 billion.
The revised guidance takes into account the gains from Chemours’ transformation plan initiatives, reduced transformation-related costs in the second half and strength across the company’s major end markets.
Chemours is expected to benefit from strength across its portfolio and improving end market conditions through the remainder of 2017. It is also well placed to gain from its sustained efforts to reduce costs, improve cash generation and strengthen the balance sheet. Moreover, the company is anticipated to continue to benefit from increased customer adoption of both Ti-Pure titanium dioxide and Opteon refrigerants.
Chemours is a Zacks Rank #1 (Strong Buy) stock.
Chemours Company (The) Price and Consensus
Chemours Company (The) Price and Consensus | Chemours Company (The) Quote
Other Stocks to Consider
Other stocks in the basic materials space worth considering include Kraton Corporation , FMC Corporation (FMC - Free Report) and Orion Engineered Carbons, S.A. (OEC - Free Report) , all sporting a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Kraton has expected earnings growth of 7.2% for the current year.
FMC has expected long-term earnings growth of 11.3%.
Orion Engineered Carbons has expected earnings growth of 19% for the current year.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>